Cogent Biosciences, Inc.
COGT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001622229
In the last 90 days, Cogent Biosciences, Inc. insiders filed 0 open-market purchases and 1 sale; 322 institutions reported holding it in 13F filings for Q2 2026, worth $7.50B in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Cogent Biosciences, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 134 | 135 | +1 |
| Shares | 74.4M | 74.9M | +480.4K (+0.6%) |
| Value | $1.10B | $864.1M | −$239.0M (−21.7%) |
New holders (22)
Institutions that held Cogent Biosciences, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (21)
Institutions that held Cogent Biosciences, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Avidity Partners Management LP | 1,357,700 | $20.3M |
| Balyasny Asset Management LLC | 1,049,542 | $15.7M |
| Point72 Asset Management, L.P. | 357,200 | $5.33M |
| EAM Investors, LLC | 337,777 | $5.04M |
| Voloridge Investment Management, LLC | 288,567 | $4.30M |
| AXA S.A. | 285,210 | $4.26M |
| Ally Bridge Group (NY) LLC | 204,014 | $3.04M |
| BNP Paribas Arbitrage, SA | 175,767 | $2.62M |
| EAM Global Investors LLC | 122,938 | $1.83M |
| Alpha Paradigm Partners, LLC | 76,348 | $1.14M |
| Woodline Partners LP | 69,871 | $1.04M |
| SEI Investments Co | 37,810 | $564.0K |
| Fred Alger Management, LLC | 31,409 | $469.0K |
| Jane Street Group, LLC | 28,506 | $425.0K |
| Boothbay Fund Management, LLC | 19,752 | $295.0K |
| Fox Run Management, L.L.C. | 18,621 | $278.0K |
| Renaissance Technologies LLC | 15,168 | $226.0K |
| Wells Fargo & Company | 1,702 | $26.0K |
| High Net Worth Advisory Group LLC | 1,500 | $22.0K |
| Ellevest, Inc. | 7 | $0 |
| Parallel Advisors, LLC | 8 | $0 |